PMID- 38314402
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240206
IS  - 2352-3204 (Electronic)
IS  - 2352-3204 (Linking)
VI  - 25
DP  - 2024 Mar
TI  - Dynamic tracking of human umbilical cord mesenchymal stem cells (hUC-MSCs) 
      following intravenous administration in mice model.
PG  - 273-283
LID - 10.1016/j.reth.2024.01.003 [doi]
AB  - INTRODUCTION: In the past decades, human umbilical cord-derived mesenchymal stem 
      cells (hUC-MSCs) have sparked interest in cellular therapy due to their 
      immunomodulatory properties. Nevertheless, the fate of hUC-MSCs in the body 
      remains poorly understood. This study aimed to investigate the biodistribution, 
      homing and clearance of systemically administered hUC-MSCs in healthy BALB/c mice 
      model. METHODS: hUC-MSCs were labelled with GFP-Luc2 protein, followed by 
      characterisation with flow cytometry. Upon intravenous infusion of transduced 
      hUC-MSCs into the healthy BALB/c mice, the cells were dynamically monitored 
      through the bioluminescent imaging (BLI) approach. RESULTS: Transduction of 
      hUC-MSCs with GFP-Luc2 not only preserved the characteristics of MSCs, but also 
      allowed live monitoring of transduced cells in the mice model. Upon systemic 
      administration, BLI showed that transduced hUC-MSCs first localised predominantly 
      in the lungs of healthy BALB/c mice and mainly remained in the lungs for up to 3 
      days before eventually cleared from the body. At terminal sacrifice, plasma 
      chemistry biomarkers remained unchanged except for C-peptide levels, which were 
      significantly reduced in the hUC-MSCs group. Histopathological findings further 
      revealed that hUC-MSCs infusion did not cause any adverse effects and toxicity to 
      lung, liver and heart tissues. CONCLUSIONS: Collectively, systemically 
      administrated hUC-MSCs was safe and demonstrated dynamic homing capacity before 
      eventually disappearing from the body.
CI  - (c) 2024 The Japanese Society for Regenerative Medicine. Production and hosting by 
      Elsevier B.V.
FAU - Chin, Sze-Piaw
AU  - Chin SP
AD  - Cytopeutics Sdn Bhd, Cyberjaya, Selangor, Malaysia.
AD  - M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul 
      Rahman, Sungai Long, Selangor, Malaysia.
FAU - Marzuki, Marini
AU  - Marzuki M
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      NIH, Setia Alam, Selangor, Malaysia.
FAU - Tai, Lihui
AU  - Tai L
AD  - Cytopeutics Sdn Bhd, Cyberjaya, Selangor, Malaysia.
FAU - Mohamed Shahrehan, Nurul Ashikin
AU  - Mohamed Shahrehan NA
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      NIH, Setia Alam, Selangor, Malaysia.
FAU - Ricky, Christine
AU  - Ricky C
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      NIH, Setia Alam, Selangor, Malaysia.
FAU - Fanty, Audrey
AU  - Fanty A
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      NIH, Setia Alam, Selangor, Malaysia.
FAU - Salleh, Annas
AU  - Salleh A
AD  - Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, 
      Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
FAU - Low, Chui Thean
AU  - Low CT
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      NIH, Setia Alam, Selangor, Malaysia.
FAU - Then, Kong-Yong
AU  - Then KY
AD  - Cytopeutics Sdn Bhd, Cyberjaya, Selangor, Malaysia.
FAU - Hoe, Susan Ling Ling
AU  - Hoe SLL
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      NIH, Setia Alam, Selangor, Malaysia.
FAU - Cheong, Soon Keng
AU  - Cheong SK
AD  - M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul 
      Rahman, Sungai Long, Selangor, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20240124
PL  - Netherlands
TA  - Regen Ther
JT  - Regenerative therapy
JID - 101709085
PMC - PMC10834363
OTO - NOTNLM
OT  - Biodistribution
OT  - GFP-Luc2
OT  - Human umbilical cord mesenchymal stem cell
COIS- SP Chin advices Cytopeutics on regulatory, clinical and research activities. 
      Information pertaining to writing assistance: No funded writing assistance was 
      utilized in the production of this manuscript.
EDAT- 2024/02/05 06:43
MHDA- 2024/02/05 06:44
PMCR- 2024/01/24
CRDT- 2024/02/05 05:06
PHST- 2023/11/30 00:00 [received]
PHST- 2024/01/07 00:00 [revised]
PHST- 2024/01/18 00:00 [accepted]
PHST- 2024/02/05 06:44 [medline]
PHST- 2024/02/05 06:43 [pubmed]
PHST- 2024/02/05 05:06 [entrez]
PHST- 2024/01/24 00:00 [pmc-release]
AID - S2352-3204(24)00003-8 [pii]
AID - 10.1016/j.reth.2024.01.003 [doi]
PST - epublish
SO  - Regen Ther. 2024 Jan 24;25:273-283. doi: 10.1016/j.reth.2024.01.003. eCollection 
      2024 Mar.